

1 **The CRAC channel inhibitor Auxora interrupts inflammatory circuits between alveolar**
2 **macrophages and T cells in patients with viral pneumonia**

3
4 S. Marina Casalino Matsuda^{1*}, Vijeeth Guggilla^{2*}, Catherine A. Gao¹, Kaitlyn E. Demeulenaere³,
5 Luisa Cusick¹, Samuel W. Fenske¹, Zhan Yu¹, Ziyang Lu¹, Suchitra Swaminathan¹, Rogan A.
6 Grant¹, Maxwell J. Schleck¹, Murali Prakriya³, Sudarshan Hebbar⁴, Kenneth Stauderman⁴, Helen
7 K. Donnelly¹, Chiagozie I. Pickens¹, Luisa Morales-Nebreda¹, The NU SCRIPT Study
8 Investigators, Richard G. Wunderink^{1#}, Alexander V. Misharin^{1#}, Benjamin D. Singer^{1#}, G.R. Scott
9 Budinger^{1,5#}

10 ¹ Division of Pulmonary and Critical Care Medicine, Department of Medicine, Northwestern
11 University Feinberg School of Medicine, Chicago, IL, USA

12 ² Health Sciences Integrated Program, Health and Biomedical Informatics Track, Northwestern
13 University Feinberg School of Medicine, Chicago, IL, USA

14 ³ Department of Pharmacology, Northwestern University Feinberg School of Medicine, Chicago,
15 IL, USA.

16 ⁴ CalciMedica, Inc, La Jolla, CA, USA

17 ⁵ Jesse Brown VA Medical Center, Chicago, IL, USA

18 *SMCM and VG contributed equally to this work

19 #RGW, AVM, BDS, and GRSB contributed equally to this work

20

21

22 **Abstract**

23 Viral pneumonia is perpetuated by inflammatory circuits between activated T cells and
24 monocyte-derived alveolar macrophages (MoAM). T cells and macrophages express ORAI1 and
25 STIM1, which form calcium release-activated calcium (CRAC) channels that allow extracellular
26 calcium entry in response to endoplasmic reticulum calcium store depletion. In a randomized,
27 placebo-controlled, multicenter phase 2 trial (CARDEA), Auxora, a CRAC channel inhibitor,
28 reduced all-cause 30-day mortality by 56% in patients with severe SARS-CoV-2 pneumonia.
29 Here, we report a multi-omics analysis of serially collected alveolar samples from unvaccinated
30 patients with severe SARS-CoV-2 pneumonia treated with Auxora versus placebo. We found
31 reductions in plasma levels of the monocyte- and T cell-chemokines, CCL8 and PDGF-AA. Using
32 peripheral blood mononuclear cells (PBMC) from healthy volunteers, we show that Auxora directly
33 targets T cells to inhibit the transcription of *CCL8* and *PDGFA* in monocyte-derived macrophages,
34 supporting a mechanism for its effects and a potential intermediate biomarker of efficacy.

35

36 Main

37 In previous reports, we analyzed alveolar samples from patients with severe SARS-CoV-
38 2 pneumonia using flow cytometry, bulk and single-cell RNA-sequencing (scRNA-seq), and
39 cytokine profiling¹⁻³. From these data, we generated a model to explain the pathobiology of severe
40 SARS-CoV-2 pneumonia: tissue-resident alveolar macrophages infected with SARS-CoV-2
41 recruit and activate coronavirus-reactive T cells that produce interferon- γ (IFN- γ). IFN- γ further
42 activates tissue-resident alveolar macrophages and drives their apoptosis. Newly recruited
43 monocytes then differentiate into MoAM, which in turn also become infected and activated,
44 creating a self-sustaining inflammatory signaling loop that drives immunopathology⁴. This model
45 was subsequently credentialed by others in a murine model of influenza pneumonia⁵ and
46 validated in a precision-cut human lung slice model⁶.

47 CRAC channels are required for T cell activation and contribute to macrophage
48 inflammatory responses⁷⁻⁹. These channels are activated when STIM1 in the endoplasmic
49 reticulum (ER) is activated in response to ER calcium store depletion. STIM1 then forms a
50 complex with ORAI1, the pore forming unit of the CRAC channel that allows entry of extracellular
51 calcium¹⁰. Before safe, effective vaccines protecting against severe SARS-CoV-2 pneumonia
52 were available, we and other investigators enrolled patients with COVID-19 requiring
53 hospitalization and supplemental oxygen in a randomized, placebo-controlled, multi-center phase
54 2 trial of Auxora (CARDEA), which resulted in a 56% reduction in 30-day all-cause mortality¹¹. All
55 patients in the trial received corticosteroids, and some received other immunomodulatory
56 therapies for COVID-19. These promising phase 2 results have prompted ongoing trials of Auxora
57 in other critically ill patients.

58
59 Concurrent with the CARDEA trial, we designed and enrolled patients with laboratory-
60 confirmed SARS-CoV-2 pneumonia complicated by the acute respiratory distress syndrome in a
61 single-center, placebo-controlled, ascending-dose phase 2 clinical trial to generate
62 pharmacokinetic (PK) and pharmacodynamic (PD) data in critically ill, mechanically ventilated
63 patients (NCT04661540) (**Fig. 1a**). Inclusion and exclusion criteria, study design and enrollment,
64 and patient demographics are found in the online supplement (**Supplementary Fig. 1 and**
65 **Supplementary Table 1**). SARS-CoV-2 viral titers estimated from the RT-qPCR cycle threshold
66 of BAL fluid did not differ in patients receiving Auxora or placebo (**Fig. 1b**). Mortality and duration
67 of ventilation did not differ in patients who received Auxora or placebo, but the only patients to be
68 discharged alive and off ventilation by day 30 received Auxora (**Fig. 1c**). Plasma levels of Auxora
69 are shown in **Fig. 1d**. BAL fluid levels of Auxora were below the limit of detection in all but 3
70 samples. We measured plasma levels of 72 cytokines, 55 of which were of sufficient quality for
71 downstream analysis². The levels of CCL8 (aka MIP-2) which is nearly exclusively produced by
72 macrophages and involved in the recruitment of monocytes, and PDGF-AA a mitogen and
73 chemoattractant of mesenchymal cells, were significantly reduced after receiving Auxora but not
74 placebo (**Fig. 1e**).

75
76 Auxora treatment did not result in substantial differences in BAL fluid immune cell
77 composition measured by flow cytometry (**Fig. 1f, Supplementary Fig. 2**). For scRNA-seq on
78 BAL fluid cells, we clustered and annotated cells as previously described (**Fig. 1g and**

79 **Supplementary Figs. 3a,b**). Consistent with our flow cytometry results, we did not detect
80 substantial differences in the cellular composition of the BAL fluid after treatment with Auxora
81 (**Supplementary Fig. 3b**). We did not detect differences in gene expression in any cell population
82 as a function of Auxora treatment (**Supplementary Fig. 3c**). *CCL8* expression was limited to
83 alveolar macrophages, and while the differences did not reach statistical significance, *CCL8* were
84 lower in MoAM from patients treated with Auxora compared with their pretreatment baseline (**Fig.**
85 **1h**). SARS-CoV-2 transcripts were detected in MoAM at baseline and were nearly absent across
86 all cell types following Auxora treatment. Differential expression testing was not performed for viral
87 genes due to sparse expression and near absence of detectable viral RNA in post-treatment
88 samples (**Fig. 1h**).

89
90 Both alveolar macrophages and T cells express *ORAI1* and *STIM1* (**Fig. 1h**). We
91 compared the pharmacodynamic responses of T cells and macrophages to Auxora using PBMC
92 from healthy volunteers after differentiating monocytes into monocyte-derived macrophages
93 (MDM). In T cells, we found that Auxora blocked Ca^{+2} entry in a dose-dependent fashion beginning
94 at a concentration of 50 nM (**Figs. 2a-c**). In contrast, Auxora inhibited CRAC channel-mediated
95 Ca^{+2} entry in MDM at a concentration of 500 nM (**Figs. 2d-f**).

96
97 We sought to test whether Auxora inhibits inflammatory circuits between MDM and T cells,
98 and if so, whether it targets T cells, MDM, or both. We cultured PBMC from healthy volunteers for
99 24 hours, then treated them with Auxora (500 nM) or vehicle, followed 2 hours later by anti-
100 CD3/CD28 antibodies or IFN- γ , and processed them for scRNA-seq 24 hours later (**Fig. 2g**;
101 **Supplementary Figs. 4a-d**). Auxora did not induce cytotoxicity at this concentration
102 (**Supplementary Fig. 4a**). Principal component analysis (PCA) revealed that treatment with anti-
103 CD3/CD28 antibodies induced transcriptional reprogramming in CD4 and CD8 T cells and MDM
104 that was attenuated by Auxora (**Figs. 2h, j, and l**). We identified large numbers of differentially
105 expressed genes in CD4 and CD8 T cells and MDM treated anti-CD3/CD28 antibodies, a majority
106 of which were affected by Auxora (**Supplementary Fig. 5a**). Genes attenuated by Auxora
107 included those encoding secreted cytokines involved in T cell activation, for example *IL2* and *TNF*,
108 and *IFNG* (**Figs. 2i, k, and m**). GSEA revealed activation of several common inflammatory
109 pathways in T cells and MDMs that were inhibited by Auxora, for example, TNF α signaling via
110 NF κ B and IL2 Stat5 signaling (**Supplementary Figs. 5b-c**).

111
112 As MDMs do not express CD3 or CD28, their activation in response to anti-CD3/CD28
113 antibodies is likely attributable to indirect signals from T cells (**Figs. 2m-o and Supplementary**
114 **Fig. 4g**). Accordingly, we sought to test whether the inhibitory effects of Auxora on MDM were
115 mediated by its effects on T cells or a direct effect on MDM. We observed no effect of Auxora
116 when we treated MDM with TLR agonists in the absence of T cells (**Supplementary Figs. 6a-b**).
117 We then examined the effect of Auxora on the response of T cells and MDM to recombinant IFN-
118 γ , the primary cytokine released by T cells in the single-cell data (**Supplementary Figs. 4e-g**).
119 Only a small fraction of the genes induced in T cells by anti-CD3/CD28 antibodies were induced
120 by IFN- γ . In contrast, genes induced in MDM treated with IFN- γ substantially overlapped with
121 those induced by anti-CD3/CD28 antibodies and IFN- γ in MDM (**Figs. 2n-o**). These results
122 suggest that Auxora targets T cells to interrupt inflammatory circuits with MoAM, mediated in large

123 part by IFN- γ . Identifying pneumonia endotypes characterized by similar circuits might guide the
124 selection of patients for future clinical trials of Auxora in patients with pneumonia.

125
126
127

128 **References**

129

- 130 1 Grant, R. A. *et al.* Circuits between infected macrophages and T cells in SARS-CoV-2
131 pneumonia. *Nature* **590**, 635-641 (2021). [https://doi.org:10.1038/s41586-020-03148-w](https://doi.org/10.1038/s41586-020-03148-w)
- 132 2 Grant, R. A. *et al.* Prolonged exposure to lung-derived cytokines is associated with
133 activation of microglia in patients with COVID-19. *JCI Insight* **9** (2024).
134 [https://doi.org:10.1172/jci.insight.178859](https://doi.org/10.1172/jci.insight.178859)
- 135 3 Markov, N. S. *et al.* Distinctive evolution of alveolar T cell responses is associated with
136 clinical outcomes in unvaccinated patients with SARS-CoV-2 pneumonia. *Nature*
137 *immunology* **25**, 1607-1622 (2024). [https://doi.org:10.1038/s41590-024-01914-w](https://doi.org/10.1038/s41590-024-01914-w)
- 138 4 Budinger, G. R. S., Misharin, A. V., Ridge, K. M., Singer, B. D. & Wunderink, R. G. Distinctive
139 features of severe SARS-CoV-2 pneumonia. *J Clin Invest* **131** (2021).
140 [https://doi.org:10.1172/JCI149412](https://doi.org/10.1172/JCI149412)
- 141 5 Narasimhan, H. *et al.* An aberrant immune-epithelial progenitor niche drives viral lung
142 sequelae. *Nature* **634**, 961-969 (2024). [https://doi.org:10.1038/s41586-024-07926-8](https://doi.org/10.1038/s41586-024-07926-8)
- 143 6 Wu, T. T. *et al.* Interstitial macrophages are a focus of viral takeover and inflammation in
144 COVID-19 initiation in human lung. *J Exp Med* **221** (2024).
145 [https://doi.org:10.1084/jem.20232192](https://doi.org/10.1084/jem.20232192)
- 146 7 Feske, S. *et al.* A mutation in Orai1 causes immune deficiency by abrogating CRAC channel
147 function. *Nature* **441**, 179-185 (2006). [https://doi.org:10.1038/nature04702](https://doi.org/10.1038/nature04702)
- 148 8 Soberanes, S. *et al.* Metformin Targets Mitochondrial Electron Transport to Reduce Air-
149 Pollution-Induced Thrombosis. *Cell Metab* **29**, 503 (2019).
150 [https://doi.org:10.1016/j.cmet.2018.12.001](https://doi.org/10.1016/j.cmet.2018.12.001)
- 151 9 Prakriya, M. The molecular physiology of CRAC channels. *Immunol Rev* **231**, 88-98 (2009).
152 [https://doi.org:10.1111/j.1600-065X.2009.00820.x](https://doi.org/10.1111/j.1600-065X.2009.00820.x)
- 153 10 Prakriya, M. *et al.* Orai1 is an essential pore subunit of the CRAC channel. *Nature* **443**, 230-
154 233 (2006). [https://doi.org:10.1038/nature05122](https://doi.org/10.1038/nature05122)
- 155 11 Bruen, C. *et al.* Auxora vs. placebo for the treatment of patients with severe COVID-19
156 pneumonia: a randomized-controlled clinical trial. *Critical care* **26**, 101 (2022).
157 [https://doi.org:10.1186/s13054-022-03964-8](https://doi.org/10.1186/s13054-022-03964-8)

158

159

160

161 **Figure Legends:**

162

163 **Figure 1: Auxora decreases levels of CCL8 and PDGF-AA in plasma of patients with severe**
164 **SARS-CoV-2 pneumonia.** **a**, Schematic illustrating protocol driven interventions. The number of
165 patients in each cohort and treatment group is indicated. Time 0 is defined by the initial BAL and
166 drug infusion. **b**, Viral load before and after placebo or Auxora infusion estimated by PCR cycle
167 threshold in BAL fluid samples. **c**, Swimmer plots of the ICU course in patients enrolled in the
168 trial. Sequential organ failure assessment (SOFA) score, assessment of viral clearance, initiation
169 of extracorporeal membrane oxygenation (ECMO), ventilator associated pneumonia episode
170 (VAP). **d**, Auxora total concentrations in plasma. **e**, Plasma CCL8 and PDGF-AA levels before
171 and after placebo or Auxora infusion. Significance determined by linear mixed models using a
172 paired design. **f**, Cell abundance measured by flow cytometry analysis of BAL samples. Samples
173 were clustered by Manhattan distance using complete linkage. **g**, Uniform manifold approximation
174 and projection (UMAP) plot showing integrated analysis of BAL cells from patients with severe
175 SARS (n = 9). **h**, Dot plot of *ORAI1*, *STIM1*, *CCL8*, PDGF-AA, and SARS-CoV-2 genes, in different
176 cell types before and after Auxora treatment. Differences were not significant based on differential
177 gene expression analysis using DESeq2 (q > 0.05, Wald test with FDR correction). Statistical
178 testing not performed for SARS-CoV-2 genes due to sparse expression.

179 **Figure 2: Auxora targets T cells to inhibit T cell-macrophage circuits during SARS-CoV-2**
180 **pneumonia.** **a-f**, We measured store-operated calcium entry (SOCE) in Fura-2 loaded cells by
181 administering thapsigargin (Tg, 1 μ M) in Ca²⁺-free solution followed by the addition of extracellular
182 Ca²⁺ (2 mM) containing media. **a**, Time course of calcium measures in peripheral T cells. **b**, Rate
183 of calcium influx after addition of extracellular Ca²⁺ following store depletion. **c**, Total amount of
184 calcium over baseline entering the cell in the five minutes after switch to Ca²⁺ (2 mM) containing
185 media. **d-f**, same as **a-c** in monocyte-derived macrophages (MDM). PBMCs were isolated from 3
186 different healthy donors. Bar graphs represent mean \pm SEM. T cells, untreated n = 16 cells; 50
187 nM Auxora n = 18 cells; 500 nM Auxora n = 19 cells. MDM, untreated n = 9 cells; 50 nM Auxora
188 n = 10 cells; 500 nM Auxora n = 22 cells. **g**, Schematic for experiments in PBMCs from 5 different
189 blood donors in **h-o**. **h-m**, Genes were identified as differentially expressed by a negative
190 binomial generalized linear model using an ANOVA-like test for differential expression between
191 any conditions in the dataset (FDR q < 0.05), Ax=Auxora. **h**, PCA of differentially expressed genes
192 in CD4 T cells. **j**, CD8 T cells **l**, MDM. **i**, Heat map demonstrating the expression of selected genes
193 of interest among the differentially expressed genes in CD4 T cells, **k**, CD8 T cells and **m**, MDM.
194 **n**, Heatmap showing the number of differentially expressed genes for each comparison. **o**, Venn
195 diagrams indicate overlap between differentially expressed genes induced by treatment with anti
196 CD3/CD8 antibodies or recombinant IFN- γ .

197

198 **Acknowledgments**

199 C.A.G. is supported by NIH/NHLBI K23HL169815, a Parker B. Francis Opportunity Award, and
200 an American Thoracic Society Unrestricted Grant. R.G.W. is supported by NIH/NIAID U19
201 AI135964, R01 AI158530; NHLBI R01 HL149883, P01 HL154998; U01TR003528. B.D.S. is
202 supported by NIH awards R01HL149883, R01HL153122, P01HL154998, P01AG049665,
203 U19AI135964, and U19AI181102. G.R.S.B. is supported by the NIH (U19AI135964,
204 P01AG049665, R01HL147575, P01HL071643, U54AG079754, R01HL145478, R01HL147290,
205 R01HL173940, U19AI181102, and R01HL154686); the US Department of Veterans Affairs
206 (I01CX001777); Simpson Querrey Lung Institute for Translational Sciences. A.V.M. was
207 supported by the NIH (grant nos. U19AI135964, P01AG049665, P01HL154998, P01HL169188,
208 U19AI181102, R01HL153312, R01HL158139, and R01ES034350), and research grants from
209 AbbVie and Merck.

210 We thank all patients and volunteers who provided their samples and data for this study and their
211 families. This research was supported in part through a generous gift from Kimberly Querrey and
212 Louis A. Simpson. This research was supported by the Simpson Querrey Lung Institute for
213 Translational Science (SQLIFTS), Northwestern University. This research was also supported by
214 the computational resources and staff contributions provided for the Quest high-performance
215 computing facility at Northwestern University, which is jointly supported by the Office of the
216 Provost, the Office for Research and Northwestern University Information Technology. This
217 research was also supported in part through the computational resources and staff contributions
218 provided by the Genomics Compute Cluster, which is jointly supported by the Feinberg School of
219 Medicine, the Center for Genetic Medicine and Feinberg's Department of Biochemistry and
220 Molecular Genetics, the Office of the Provost, the Office for Research and Northwestern
221 Information Technology. The Genomics Compute Cluster is part of Quest, Northwestern
222 University's high-performance computing facility, with the purpose of advancing research in
223 genomics. Northwestern University Flow Cytometry Core Facility is supported by the National
224 Cancer Institute Cancer Center support grant (no. P30 CA060553) awarded to the Robert H. Lurie
225 Comprehensive Cancer Center. Sorting was performed on a BD FACS Aria SORP cell sorter
226 purchased with the support of the National Institutes of Health (NIH, grant no. 1S10OD011996-
227 01). Integrative genomic services were performed by the Metabolomics Core Facility at Robert H.
228 Lurie Comprehensive Cancer Center of Northwestern University.

229

230 **Author contributions**

231 Conceptualization: S.M.C.M., R.G.W., B.D.S., G.R.S.B., and A.V.M. Methodology: S.M.C.M.,
232 V.G., C.A.G., R.G.W., and A.V.M. Software: S.M.C.M., V.G., C.A.G., L.C., S.W.F., M.S. and A.V.M.
233 Validation: S.M.C.M., V.G., C.A.G., R.G.W., and A.V.M. Formal analysis: S.M.C.M., V.G., C.A.G.,
234 L.C., S.W.F., R.G.W., and A.V.M. Investigation: S.M.C.M., C.A.G., K.D., Z.Y., Z.L., R.A.G., H.K.D.,
235 R.G.W., and A.V.M. Resources: S.M.C.M., V.G., C.A.G., K.D., Z.Y., Z.L., S.S., R.A.G., M.P., S.H.,
236 K.S., H.K.D., C.I.P., L.M.-N., R.G.W., B.D.S., G.R.S.B. and A.V.M. Data curation: S.M.C.M., V.G.,
237 C.A.G., L.C., Z.Y., Z.L., R.G.W., B.D.S., G.R.S.B. and A.V.M. Writing – all aspects: S.M.C.M.,
238 R.G.W., B.D.S., G.R.S.B., and A.V.M. Writing – review & editing: S.M.C.M. Visualization:
239 S.M.C.M. and V.G. Supervision: S.M.C.M., R.G.W., G.R.S.B., B.D.S., and A.V.M. Project
240 administration: S.M.C.M., R.G.W., B.D.S., G.R.S.B., and A.V.M. Funding acquisition: R.G.W.,
241 B.D.S., G.R.S.B., and A.V.M.



